<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978029</url>
  </required_header>
  <id_info>
    <org_study_id>P06081</org_study_id>
    <secondary_id>MK-3641-004</secondary_id>
    <nct_id>NCT00978029</nct_id>
  </id_info>
  <brief_title>Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)</brief_title>
  <official_title>A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis (Protocol No. P06081)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the safety and tolerability of a ragweed allergy
      immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years
      of age and older with ragweed-induced rhinoconjunctivitis, with or without asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Participants Reporting Treatment-emergent Adverse Events (AEs)</measure>
    <time_frame>Up to Day 42</time_frame>
    <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with treatment-emergent AEs were recorded. An AE is any unfavorable and unintended sign, symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent AEs are new AEs that occur after participants have been randomized into the trial, or existing AEs that occurred during Screening that increase in severity after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Reporting Oral Pruritus</measure>
    <time_frame>Up to Day 42</time_frame>
    <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with oral pruritus were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Reporting Ear Pruritus</measure>
    <time_frame>Up to Day 42</time_frame>
    <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with ear pruritus were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Reporting Throat Irritation</measure>
    <time_frame>Up to Day 42</time_frame>
    <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with throat irritation were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Reporting Mouth Oedema</measure>
    <time_frame>Up to Day 42</time_frame>
    <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with mouth oedema were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Discontinued Due to Adverse Events.</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with AEs leading to study discontinuation were reported. An AE is any unfavorable and unintended sign, symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Rhinitis</condition>
  <condition>Conjunctivitis</condition>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet sublingual, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCH 39641 6 Amb a 1-U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCH 39641 12 Amb a 1-U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sublingual tablet, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SCH 39641</intervention_name>
    <description>Allergy immunotherapy tablet (sublingual)</description>
    <arm_group_label>SCH 39641 6 Amb a 1-U</arm_group_label>
    <other_name>MK-3641</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SCH 39641</intervention_name>
    <description>Allergy immunotherapy tablet (sublingual)</description>
    <arm_group_label>SCH 39641 12 Amb a 1-U</arm_group_label>
    <other_name>MK-3641</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 50 years of age or older, of either sex, and of any race/ethnicity.

          -  Subject must have a clinical history of ragweed-induced allergic rhinoconjunctivitis
             with or without asthma.

          -  Subject must have a positive skin prick test response to Ambrosia artemisiifolia at
             the Screening Visit

          -  Subject must have a forced expiratory volume in 1 second (FEV1) of at least 70% of
             predicted value at the Screening Visit and at Randomization.

          -  A subject's clinical laboratory tests, electrocardiogram (ECG) and vital signs
             conducted at the Screening Visit must be within normal limits or clinically acceptable
             to the investigator.

        Exclusion Criteria:

          -  Subject with asthma who requires inhaled corticosteroids for the treatment of their
             asthma during the study period.

          -  Subject requiring anti-allergy medications during the time period from randomization
             to study completion.

          -  Subject who has received an immunosuppressive treatment within 3 months prior to the
             Screening Visit (except steroids for allergic and asthma symptoms).

          -  Subject with a history of anaphylaxis with cardiorespiratory symptoms.

          -  Subject with a history of chronic urticaria or angioedema.

          -  Subject with current severe atopic dermatitis.

          -  Female subject who is breastfeeding, pregnant, or intending to become pregnant.

          -  Subject with a history of allergy, hypersensitivity or intolerance to the ingredients
             of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia),
             or self-injectable epinephrine.

          -  Subject with a history of self-injectable epinephrine use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <results_first_submitted>April 25, 2014</results_first_submitted>
  <results_first_submitted_qc>April 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2014</results_first_posted>
  <disposition_first_submitted>April 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2010</disposition_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Due to non-compliance with Good Clinical Practice (GCP) 7 randomized participants who completed treatment were excluded from all subsequent analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo tablet sublingual, once daily</description>
        </group>
        <group group_id="P2">
          <title>SCH 39641 6 Amb a 1-U</title>
          <description>6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an Allergy Immunotherapy Tablet (AIT) sublingual, once daily</description>
        </group>
        <group group_id="P3">
          <title>SCH 39641 12 Amb a 1-U</title>
          <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching placebo tablet sublingual, once daily</description>
        </group>
        <group group_id="B2">
          <title>SCH 39641 6 Amb a 1-U</title>
          <description>6 Amb a 1-U in an AIT, sublingual, once daily</description>
        </group>
        <group group_id="B3">
          <title>SCH 39641 12 Amb a 1-U</title>
          <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="196"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="4.7"/>
                    <measurement group_id="B2" value="56.4" spread="5.4"/>
                    <measurement group_id="B3" value="56.2" spread="5.7"/>
                    <measurement group_id="B4" value="56.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Participants Reporting Treatment-emergent Adverse Events (AEs)</title>
        <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with treatment-emergent AEs were recorded. An AE is any unfavorable and unintended sign, symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent AEs are new AEs that occur after participants have been randomized into the trial, or existing AEs that occurred during Screening that increase in severity after randomization.</description>
        <time_frame>Up to Day 42</time_frame>
        <population>All subjects as treated (ASAT) consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet sublingual, once daily</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>6 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Participants Reporting Treatment-emergent Adverse Events (AEs)</title>
          <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with treatment-emergent AEs were recorded. An AE is any unfavorable and unintended sign, symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-emergent AEs are new AEs that occur after participants have been randomized into the trial, or existing AEs that occurred during Screening that increase in severity after randomization.</description>
          <population>All subjects as treated (ASAT) consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
          <units>Proportion of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.446"/>
                    <measurement group_id="O2" value="0.515"/>
                    <measurement group_id="O3" value="0.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.486</p_value>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>6.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.17</ci_lower_limit>
            <ci_upper_limit>23.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>Fisher Exact</method>
            <param_type>Percent Difference</param_type>
            <param_value>16.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>33.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Reporting Oral Pruritus</title>
        <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with oral pruritus were reported.</description>
        <time_frame>Up to Day 42</time_frame>
        <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet sublingual, once daily</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>6 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Reporting Oral Pruritus</title>
          <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with oral pruritus were reported.</description>
          <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
          <units>Proportion of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015"/>
                    <measurement group_id="O2" value="0.167"/>
                    <measurement group_id="O3" value="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Reporting Ear Pruritus</title>
        <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with ear pruritus were reported.</description>
        <time_frame>Up to Day 42</time_frame>
        <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet sublingual, once daily</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>6 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Reporting Ear Pruritus</title>
          <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with ear pruritus were reported.</description>
          <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
          <units>Proportion of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.061"/>
                    <measurement group_id="O3" value="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Reporting Throat Irritation</title>
        <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with throat irritation were reported.</description>
        <time_frame>Up to Day 42</time_frame>
        <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet sublingual, once daily</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>6 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Reporting Throat Irritation</title>
          <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with throat irritation were reported.</description>
          <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
          <units>Proportion of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015"/>
                    <measurement group_id="O2" value="0.121"/>
                    <measurement group_id="O3" value="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Reporting Mouth Oedema</title>
        <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with mouth oedema were reported.</description>
        <time_frame>Up to Day 42</time_frame>
        <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet sublingual, once daily</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>6 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Reporting Mouth Oedema</title>
          <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with mouth oedema were reported.</description>
          <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
          <units>Proportion of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.015"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Who Discontinued Due to Adverse Events.</title>
        <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with AEs leading to study discontinuation were reported. An AE is any unfavorable and unintended sign, symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet sublingual, once daily</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>6 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Who Discontinued Due to Adverse Events.</title>
          <description>Participants were treated for 28 days with either 6 or 12 Units of SCH 39641 or placebo, and the proportion with AEs leading to study discontinuation were reported. An AE is any unfavorable and unintended sign, symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
          <population>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</population>
          <units>Proportion of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 42</time_frame>
      <desc>ASAT consisting of all randomized participants who received at least one dose of study treatment. Due to non-compliance with GCP 7 participants were excluded from this analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching placebo tablet sublingual, once daily</description>
        </group>
        <group group_id="E2">
          <title>SCH 39641 6 Amb a 1-U</title>
          <description>6 Amb a 1-U in an AIT, sublingual, once daily</description>
        </group>
        <group group_id="E3">
          <title>SCH 39641 12 Amb a 1-U</title>
          <description>12 Amb a 1-U in an AIT, sublingual, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E3" events="21" subjects_affected="11" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide to the sponsor for review 45 days prior to submission for publication or presentation, copies of abstracts or manuscripts for publication that report any results of the trial. If the parties disagree concerning the sponsor's confidential information, the investigator agrees to meet with the sponsor's representative, prior to submission for publication, in order to make good faith efforts to discuss and resolve any issues or disagreements.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

